rituximab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA-associated Vasculitides
Conditions
ANCA-associated Vasculitides
Trial Timeline
Mar 31, 2015 → Aug 16, 2018
NCT ID
NCT02433522About rituximab + Placebo
rituximab + Placebo is a phase 3 stage product being developed by Roche for ANCA-associated Vasculitides. The current trial status is completed. This product is registered under clinical trial identifier NCT02433522. Target conditions include ANCA-associated Vasculitides.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02433522 | Phase 3 | Completed |
| NCT01268033 | Phase 2/3 | Completed |
| NCT00372892 | Phase 2 | Completed |
Competing Products
3 competing products in ANCA-associated Vasculitides
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Amgen | Phase 2 | 51 |
| Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine | Amgen | Phase 3 | 76 |
| Abatacept (Orencia) | Bristol Myers Squibb | Phase 2 | 51 |